Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Arandomized, double-blind phase III trial (ZEPHYR)

Journal of Clinical Oncology

Volumn 30, Issue 10, 2012, Pages 1114-1121

  Lee, Jin Soo ^a   Hirsh, Vera ^c   Park, Keunchil ^b   Qin, Shukui ^d   Blajman, Cesar R ^e   Perng, Reury Perng ^f   Chen, Yuh Min ^g   Emerson, Laura ^h   Langmuir, Peter ^h   Manegold, Christian ⁱ  

^a National Cancer Center   (South Korea)

^b Samsung Medical Center   (South Korea)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Nanjing Bayi Hospital   (China)

^e Isis Centro Especializado   (Argentina)

^f Veterans General Hospital   (Taiwan)

^g NATIONAL YANG MING UNIVERSITY   (Taiwan)

^h ASTRAZENECA   (United Kingdom)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR 2; GEFITINIB; PLACEBO; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; INFECTION; INFESTATION; INSOMNIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PIPERIDINES; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOKING; TREATMENT OUTCOME;

EID: 84861720010     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1709     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005 (Pubitemid 40372904)
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
3. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
4. Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Zhou C, Wu Y-L, Chen G, et al: Efficacy results from the randomised phase III optimal (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (gem), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Ann Oncol 21:viii6, 2010 (suppl 8; abstr LBA13)
6. Ciardiello F, Bianco R, Caputo R, et al: Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784-793, 2004 (Pubitemid 38174017)
7. Tabernero J: The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203-220, 2007
8. Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290, 2002 (Pubitemid 36025251)
9. Wedge SR, Ogilvie DJ, Dukes M, et al: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-4655, 2002
10. Herbst RS, Heymach JV, O'Reilly MS, et al: Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-249, 2007 (Pubitemid 46206638)
11. Natale RB, Bodkin D, Govindan R, et al: Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized Phase II study. J Clin Oncol 27:2523-2529, 2009
12. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced nonsmall-cell lung cancer. J Clin Oncol 29:1059-1066, 2011
13. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 25:4270-4277, 2007 (Pubitemid 47548567)
14. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626, 2010
15. de Boer RH, Arrieta Ó, Yang C-H, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29:1067-1074, 2011
16. Naumov GN, Nilsson MB, Cascone T, et al: Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15: 3484-3494, 2009
17. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
18. Cella D, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002 (Pubitemid 34195525)
19. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
20. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005 (Pubitemid 40812628)
21. Kiura K, Nakagawa K, Shinkai T, et al: A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3:386-393, 2008 (Pubitemid 351489479)
22. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003 (Pubitemid 37432975)
23. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004 (Pubitemid 41095044)
24. Thatcher N, Chang A, Parikh P, et al: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537, 2005 (Pubitemid 41540110)
25. Fukuoka M, Yano S, Giaccone G, et al: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003 (Pubitemid 46621858)